Literature DB >> 3759736

The antimicrobial activity of ciprofloxacin against Legionella species and the treatment of experimental Legionella pneumonia in guinea pigs.

A Saito, H Koga, H Shigeno, K Watanabe, K Mori, S Kohno, Y Shigeno, Y Suzuyama, K Yamaguchi, M Hirota.   

Abstract

The antimicrobial activity of ciprofloxacin was tested against 15 standard reference strains, and 37 clinical and environmental strains of Legionella pneumophila by an agar dilution method, using a new growth medium (B-SYE agar) which we devised. The minimal inhibitory concentrations of ciprofloxacin were found to be inoculum dependent, and ranged from 0.02 to 0.06 mg/l at 10(4) cfu inoculum and 0.02 by 0.125 mg/l at 10(6) cfu inoculum. The most potent antibacterial activity was shown by rifampicin, followed by ofloxacin, ciprofloxacin, enoxacin, norfloxacin, erythromycin and pipemidic acid in that order. The therapeutic efficacy of ciprofloxacin in experimental guinea pig pneumonia due to L. pneumophila was fairly good with a survival rate of 80%. From other data of ours, its effectiveness in experimental pneumonia was equal to or greater than that of erythromycin. Further studies would be appropriate to investigate the possibility of using ciprofloxacin for the treatment of human L. pneumophila infection.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3759736     DOI: 10.1093/jac/18.2.251

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  19 in total

1.  Activity of temafloxacin against respiratory pathogens.

Authors:  R N Swanson; D J Hardy; D T Chu; N L Shipkowitz; J J Clement
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia.

Authors:  P H Edelstein; M A Edelstein; J Weidenfeld; M B Dorr
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

3.  Comparison of charcoal- and starch-based media for testing susceptibilities of Legionella species to macrolides, azalides, and fluoroquinolones.

Authors:  S L Pendland; S J Martin; C Chen; P C Schreckenberger; L H Danziger
Journal:  J Clin Microbiol       Date:  1997-11       Impact factor: 5.948

4.  In vitro activity and mode of action of fluoroquinolones.

Authors:  L Verbist
Journal:  Pharm Weekbl Sci       Date:  1987-12-11

5.  Efficacy of NY-198 against experimental Legionnaires disease.

Authors:  S Kohno; K Yamaguchi; Y Dohtsu; H Koga; T Hayashi; M Hirota; A Saito; K Hara
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

6.  Susceptibilities of Legionella spp. to newer antimicrobials in vitro.

Authors:  T Schülin; C B Wennersten; M J Ferraro; R C Moellering; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

7.  Enhanced elimination of ciprofloxacin after multiple-dose administration of rifampin to rabbits.

Authors:  S L Barriere; G W Kaatz; S M Seo
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

Review 8.  Treatment of Legionnaires' disease. Current recommendations.

Authors:  J Roig; A Carreres; C Domingo
Journal:  Drugs       Date:  1993-07       Impact factor: 9.546

9.  Accumulation of a newly developed fluoroquinolone, OPC-17116, by human polymorphonuclear leukocytes.

Authors:  K Taira; H Koga; S Kohno
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

10.  Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia.

Authors:  P H Edelstein; M A Edelstein; J Ren; R Polzer; R P Gladue
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.